{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "In a state that says it is already so short of public money it does not have enough to keep all the schools open and prosecute many criminals, Oregon took another drastic step this week to cover budget shortfalls: it cut off medications to thousands of schizophrenics, manic-depressives, drug addicts and others who are poor and have no health care. A decade ago, Oregon was widely hailed as a pioneer in providing health insurance, including prescription drug coverage, not only to the poor but also to people who make just enough money that they do not qualify for most federal Medicaid programs.", "headline": {"main": "A Prescription Plan Lauded as a Model Is a Budget Casualty"}, "abstract": "Oregon, widely hailed decade ago as pioneer in providing health insurance including prescription drug coverage to virtually everyone, pares back program and eliminates coverage for certain ailments after voters reject tax increase to balance budget; move leaves about 100,000 poor people suddenly scrambling for basic medications; is latest response to budget crisis that has led state officials to make nearly $600 million in cuts in last two years, and will require additional $2 billion in reductions in new budget cycle that begins in June; state has no statewide sales tax, and lacks enough money for most essential social services; while officials press efforts to restore some of health program, they admit they will be unable to offer anything like expansive benefits of past; photo (M)", "print_page": "1", "word_count": 1562, "_id": "4fd23c7a8eb7c8105d7d1e03", "snippet": "In a state that says it is already so short of public money it does not have enough to keep all the schools open and prosecute many criminals, Oregon took another drastic step this week to cover budget shortfalls: it cut off medications to thousands...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/05/us/a-prescription-plan-lauded-as-a-model-is-a-budget-casualty.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "OREGON"}, {"name": "subject", "value": "SOCIAL CONDITIONS AND TRENDS"}, {"name": "subject", "value": "HEALTH INSURANCE"}, {"name": "subject", "value": "TAXATION"}, {"name": "subject", "value": "SALES TAX"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}, {"name": "subject", "value": "ELECTIONS"}, {"name": "subject", "value": "REFERENDUMS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Timothy", "lastname": "EGAN"}], "original": "By TIMOTHY EGAN"}, "document_type": "article", "pub_date": "2003-03-05T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Many analysts have predicted a wave of mergers in the biotechnology industry. After all, many companies with promising technology now have low stock prices and are running out of money, making them takeover candidates. But while a wave of mergers appears to be starting, many of the companies being taken over recently are the opposite of what has been predicted. They have money and are being acquired for their cash rather than for their technology.", "headline": {"main": "TECHNOLOGY: Market Place; Biotech Mergers: Cash Talks Louder Than Technology"}, "abstract": "Biotechnology companies are being acquired for their cash rather than for their technology; 22 percent of industry's publicly traded biotechnology companies have market values lower than their cash levels, making it tempting for others to acquire them; Dendreon last week said it would pay $73 million in stock for Corvas International, which had $90.5 million in cash at end of December; Britain's Cambridge Antibody Technology and Celltech are bidding against each other for Oxford GlycoSciences, with both companies offering less than Oxford's cash; such deals are starting to raise some shareholder concern; chart (Market Place column) (M)", "print_page": "1", "word_count": 990, "_id": "4fd22af78eb7c8105d7b61c0", "snippet": "Many analysts have predicted a wave of mergers in the biotechnology industry. After all, many companies with promising technology now have low stock prices and are running out of money, making them takeover candidates.     But while a wave of mergers...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/05/business/technology-market-place-biotech-mergers-cash-talks-louder-than-technology.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "CELLTECH GROUP"}, {"name": "organizations", "value": "CORVAS INTERNATIONAL INC"}, {"name": "organizations", "value": "OXFORD GLYCOSCIENCES"}, {"name": "organizations", "value": "CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC"}, {"name": "organizations", "value": "DENDREON CORP"}, {"name": "subject", "value": "MERGERS, ACQUISITIONS AND DIVESTITURES"}, {"name": "subject", "value": "INDUSTRY PROFILES"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "BIOTECHNOLOGY"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2003-03-05T00:00:00Z", "section_name": "Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The White House unveiled its plan tonight to overhaul Medicare, saying it would offer comprehensive coverage of prescription drugs and preventive services to people who join private insurance plans. The Bush administration backed away from its idea to offer no drug benefits to elderly people in the traditional fee-for-service Medicare program. But drug benefits available through private plans would be far more extensive, so Medicare recipients would have strong incentives to join private plans.", "headline": {"main": "White House Unveils Plan For Medicare Drug Benefits"}, "abstract": null, "print_page": "20", "word_count": 1115, "_id": "4fd2267b8eb7c8105d7ae878", "snippet": "The White House unveiled its plan tonight to overhaul Medicare, saying it would offer comprehensive coverage of prescription drugs and preventive services to people who join private insurance plans.    The Bush administration backed away from its...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/04/us/white-house-unveils-plan-for-medicare-drug-benefits.html", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}], "original": "By ROBERT PEAR"}, "document_type": "article", "pub_date": "2003-03-04T00:00:00Z", "section_name": "U.S."}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "Charles T. Sell, a St. Louis dentist, was indicted in 1997 on counts of mail fraud, Medicaid fraud and money laundering. As the trial approached, he became agitated and paranoid. When he became too delusional to understand the charges against him or to participate in his own defense -- the threshold used for determining competence to stand trial -- prosecutors asked him to take anti-psychotic medication. Mr. Sell refused. Today the question of whether he has that right comes before the Supreme Court.", "headline": {"main": "Insanity Goes Back on Trial"}, "abstract": "Op-Ed article by Sally Satel, psychiatrist, says Supreme Court will consider whether psychotic defendant can be forced against his will to take anti-psychotic medication; says defendant Charles T Sell did not kill anyone and is being prosecuted for nonviolent offense; says his lawyers claim that imposing 'mind altering' anti-psychotic medications to induce 'synthetic sanity' breaches his liberty; says American Civil Liberties Union and others support this claim; holds it is grievously naive to depict serious mental illness as free expression of thought, or pharmacotherapy as censorship; says Sell's mental function is hostage to illness that compels him to view world through persecutory lens; notes that half the people with schizophrenia or mania do not even recognize that they are ill; says in considering Sell's case, justices must understand that freedom to be delusional is no freedom at all (M)", "print_page": "23", "word_count": 822, "_id": "4fd22af78eb7c8105d7b6223", "snippet": "Charles T. Sell, a St. Louis dentist, was indicted in 1997 on counts of mail fraud, Medicaid fraud and money laundering. As the trial approached, he became agitated and paranoid. When he became too delusional to understand the charges against him or...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/03/opinion/insanity-goes-back-on-trial.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "SELL, CHARLES T"}, {"name": "organizations", "value": "AMERICAN CIVIL LIBERTIES UNION"}, {"name": "subject", "value": "SCHIZOPHRENIA"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "CRIME AND CRIMINALS"}, {"name": "subject", "value": "FREEDOM AND HUMAN RIGHTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Sally", "lastname": "Satel"}], "original": "By Sally Satel"}, "document_type": "article", "pub_date": "2003-03-03T00:00:00Z", "section_name": "Health; Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "Money and Business/Financial Desk", "lead_paragraph": "AT this time last year, if Shalonda Welborn or a member of her family had to see a doctor, she would have had to chip in a $15 co-payment. But this year, she expects to pay no money out of pocket. Last fall, Mrs. Welborn, 32, a senior training specialist in corporate development, signed up for a new kind of health coverage, called a health reimbursement arrangement, or H.R.A. As part of the plan, her employer, CompuCom Systems, an information technology service provider in Dallas, has given her a $2,000 health care savings account that she can use to pay for medical care.", "headline": {"main": "Personal Business; A New Health Plan Works, at Least for the Healthy"}, "abstract": "Employers, insurers and experts in field are closely watching new kind of health coverage, called health reimbursement arrangements or consumer-driven plans, to see if they will cut cost of health care; such plans offer set amount of first-dollar coverage, followed by large deductible for expenses above that amount, after which insurance plan kicks in with coverage of percentage of costs; only tiny percentage of insured employees now participate in HRA's; plans have gained momentum recently; major purveyors are handful of small companies that are administrators, not insurers; photo (M)", "print_page": "8", "word_count": 1394, "_id": "4fd2267d8eb7c8105d7ae99d", "snippet": "AT this time last year, if Shalonda Welborn or a member of her family had to see a doctor, she would have had to chip in a $15 co-payment. But this year, she expects to pay no money out of pocket.    Last fall, Mrs. Welborn, 32, a senior training...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/02/business/personal-business-a-new-health-plan-works-at-least-for-the-healthy.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "FRINGE BENEFITS"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Beth", "lastname": "KOBLINER"}], "original": "By BETH KOBLINER"}, "document_type": "article", "pub_date": "2003-03-02T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The signs are conspicuous: blood-red paint on square slices of worn plywood, nailed high on leafless trees. They bear a message for all in Englewood, one of the most homicide-plagued neighborhoods in Chicago.", "headline": {"main": "In Deadly Area, Signs Urge End to Killings"}, "abstract": "Handmade signs are being put up across Englewood, mostly black, working-class neighborhood of Chicago, urging end to killing that plagues neighborhood; nearly 700 people were killed in neighborhood in last decade, and in 2002 Chicago has highest homicide rate of nine largest cities with populations over one million; Englewood residents rely on security gates and barred windows and keep children within arm's reach; some feel like prisoners in their own homes; photos (M)", "print_page": "16", "word_count": 1695, "_id": "4fd241cb8eb7c8105d7da9ed", "snippet": "The signs are conspicuous: blood-red paint on square slices of worn plywood, nailed high on leafless trees.    They bear a message for all in Englewood, one of the most homicide-plagued neighborhoods in Chicago.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/02/us/in-deadly-area-signs-urge-end-to-killings.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "CHICAGO (ILL)"}, {"name": "subject", "value": "SIGNS"}, {"name": "subject", "value": "MURDERS AND ATTEMPTED MURDERS"}, {"name": "subject", "value": "BLACKS"}], "byline": {"person": [{"firstname": "John", "middlename": "W.", "lastname": "FOUNTAIN", "rank": 1, "role": "reported", "organization": ""}], "original": "By JOHN W. FOUNTAIN"}, "document_type": "article", "pub_date": "2003-03-02T00:00:00Z", "section_name": "U.S."}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "Money is vital in combating the global AIDS epidemic, but diplomacy is key as well. Many lives hang in the balance as the world's trade ministers debate allowing poor countries continued access to cheap generic drugs. Last month, officials left a meeting in Tokyo without resolving the issue, and the stalemate has continued at talks in Geneva. President Bush's request for an additional $10 billion over the next five years to fight AIDS in Africa is great news, but the money will go much farther if poor countries can get affordable drugs. This is the problem: Patent rules adopted by the World Trade Organization in 1996 and set to come into effect gradually over the next decade will limit trade of generic drugs that compete with patented products.", "headline": {"main": "The New AIDS Fight; Generic Drugs Can Make the Money Last"}, "abstract": "World Bank managing director Mamphela Ramphele and chief economist Nicholas Stern Op-Ed article maintains diplomacy is one of keys to combating global AIDS epidemic; notes poorer countries that cannot manufacture their own drugs could be barred from importing generic versions; drawing (M)", "print_page": "19", "word_count": 663, "_id": "4fd2706e8eb7c8105d82c0f9", "snippet": "Money is vital in combating the global AIDS epidemic, but diplomacy is key as well. Many lives hang in the balance as the world's trade ministers debate allowing poor countries continued access to cheap generic drugs. Last month, officials left a...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/01/opinion/the-new-aids-fight-generic-drugs-can-make-the-money-last.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Mamphela", "lastname": "Ramphele"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Nicholas", "lastname": "Stern"}], "original": "By Mamphela Ramphele and Nicholas Stern"}, "document_type": "article", "pub_date": "2003-03-01T00:00:00Z", "section_name": "Health; Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "A senior executive at Bayer testified in court yesterday that company officials in the United States recommended against selling the anticholesterol drug Baycol several years before it was introduced in 1997 because they thought its sales potential was limited. But Baycol was introduced because officials in Germany, where Bayer is based, decided to push ahead when market conditions improved and the potential for profit looked promising for many years.", "headline": {"main": "Bayer Official Offers Defense In Texas Trial Of Drug Suit"}, "abstract": "Bayer executive Lawrence Posner tells Texas court that company officials in US recommended against selling anticholesterol drug Baycol several years before it was introduced in 1997, because they doubted sales potential; Bayer's German executives pushed marketing until drug was withdrawn in 2001 after more than 30 deaths were linked to it; Posner testifies in suit by Hollis Haltom, 82, who contracted muscle disorder rhabdomyolysis after taking Baycol (M)", "print_page": "1", "word_count": 1300, "_id": "4fd241c48eb7c8105d7da3ec", "snippet": "A senior executive at Bayer testified in court yesterday that company officials in the United States recommended against selling the anticholesterol drug Baycol several years before it was introduced in 1997 because they thought its sales potential...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/03/01/business/bayer-official-offers-defense-in-texas-trial-of-drug-suit.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "POSNER, LAWRENCE"}, {"name": "persons", "value": "HALTOM, HOLLIS"}, {"name": "organizations", "value": "BAYER AG"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "BAYCOL (DRUG)"}, {"name": "subject", "value": "RHABDOMYOLYSIS (MUSCLE DISEASE)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MUSCLES"}, {"name": "subject", "value": "CHOLESTEROL"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Melody", "lastname": "PETERSEN"}], "original": "By MELODY PETERSEN"}, "document_type": "article", "pub_date": "2003-03-01T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 8, "offset": 0, "time": 61}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}